Founded in 2010, Signal Genetics focuses on molecular diagnostics and offers the MyPRS test, a gene expression profiling assay used to assist in managing patients with multiple myeloma and related disorders. The company's diagnostic services are based on over 30 years of clinical research conducted at the University of Arkansas for Medical Sciences, resulting in their flagship product, MyPRS. Signal Genetics aims to improve patient care by providing physicians with valuable diagnostic information for cancer treatment decisions.